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Osteoclasts are polykaryons unique in their capacity to resorb 
bone (1). They are derived from monocyte/macrophage precursors 
that assume the osteoclast phenotype under the aegis of the key 
osteoclastogenic cytokine, receptor activator of NF-κB (RANK) 
ligand (RANKL) (2). RANKL and its receptor RANK (3) are respec-
tive members of the TNF superfamilies of cytokines and receptors, 
but RANKL enjoys structural features that endow it with its osteo-
clastogenic properties (4).
RANK, like other members of the TNF family of receptors, medi-
ates its intracellular signals via a group of proteins known as TNF 
receptor–associated factors (TRAFs) (5). While a number of TRAFs 
are promiscuous in associating with TNF family receptors, only 
RANK and CD40 recognize and signal through TRAF6 (6, 7). The 
fact that TRAF6 plays an essential role in osteoclastogenesis is 
established by the presence of severe osteopetrosis in mice deleted 
of the adaptor protein (8, 9). Thus, delineation of the bone resorp-
tive process requires an understanding of the means by which 
TRAF6 mediates RANK-induced osteoclastogenesis.
The LIM domain represents a protein motif characterized by 
double zinc fingers (10). It is a component of an array of mol-
ecules, many of which serve as adapters and modifiers of protein-
protein interactions. The four and a half LIM domain (FHL) sub-
family of these proteins consist of 5 members, FHL1, -2, -3, and -4 
and activator of CREM (cAMP response element modulator pro-
tein) in testis (ACT), each consisting exclusively of LIM domains 
(11). FHL proteins are not known to be expressed in bone cells or 
participate in skeletal function.
In our exploration of the means by which TRAF6 mediates osteo-
clastogenesis, we found it associates with FHL2, which is expressed 
only in activated osteoclasts in vivo. Furthermore, FHL2, by displac-
ing TRAF6 from RANK, attenuates osteoclast formation and cyto-
skeletal organization via inhibition of NF-κB. As a consequence, 
osteoclastogenesis and bone resorption are accelerated in the face 
of FHL2 deficiency. FHL2 therefore represents a physiological regu-
lator of stimulated osteoclast differentiation and skeletal mass.
Results
TRAF proteins interact with FHL2. We initially utilized TRAF4 as 
bait in a yeast 2-hybrid system. A mouse embryo cDNA library 
was screened and FHL2 revealed itself as an interesting target (not 
shown). To determine whether FHL2 also interacts with TRAFs in 
mammalian cells, we expressed FLAG-tagged TRAF2, TRAF4, and 
TRAF6 and HA-tagged FHL2 in 293T cells. The cells were lysed 
and the lysate was immunoprecipitated with anti-FLAG antibody, 
then subjected to Western blot with anti-HA antibody. To assess 
relative expression of the transfected plasmids, anti-FLAG and 
anti-HA immunoblots were generated from equal amounts of 
lysates. As seen in Figure 1A, each FLAG-tagged TRAF associates 
with FHL2-HA, but TRAF6 does so most effectively, particularly in 
light of its abundance relative to TRAFs 2 and 4.
Since TRAF6 is a crucial RANKL/RANK signaling mediator (12), 
we turned our attention to its predominant association with FHL2 
with the hypothesis that the latter may regulate osteoclast function. 
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To confirm the interaction between the 2 signaling molecules, we 
once again used 293T cells transfected with TRAF6-FLAG and 
FHL2-HA, in this instance immunoprecipitating HA and immu-
noblotting FLAG. Once again, FHL2 coimmunoprecipitates with 
TRAF6 (Figure 1B). Furthermore, the intracellular association of 
TRAF6 and FHL2, when overexpressed in 293T cells, is evident by 
immunofluorescent microscopy (Figure 1C).
All domains of FHL2 are required to interact with TRAF6. Various com-
binations of LIM domains of FHL2 are required to associate with 
individual binding partners. For example, deletion of any FHL2 
LIM domain, including its half N terminal moiety, obviates associa-
tion with the β1A integrin subunit (13). To detail the components 
of FHL2 that mediate its recognition of TRAF6, we individually 
deleted each of its LIM domains and transfected the constructs, 
as HA-tagged proteins, into 293T cells. In each circumstance, the 
cells were also transfected with TRAF6-FLAG (Figure 2A). Anti-HA 
immunoprecipitates were immunoblotted with anti-FLAG anti-
body. Once again, the full-length proteins interact, but deletion of 
any complete LIM domain or the N terminal half domain of FHL2 
ablates this association. We then turned to the domain(s) of TRAF6 
required to interact with FHL2. Thus, we transfected 293T cells 
with FLAG-tagged full-length TRAF6 or NH2 terminal deletion 
constructs lacking the ring domain (TRAF6-NR) or containing only 
the TRAF domain (TRAF6C). As seen in Figure 2B, the products of 
each TRAF6 construct immunoprecipitate with FHL2. Thus, the 
TRAF domain of TRAF6 suffices for its recognition of FHL2.
FHL2 is specifically expressed during osteoclast differentiation in 
vitro. We next asked if FHL2 is expressed in authentic osteo-
clasts in vitro. To this end, we cultured WT and FHL2–/– bone 
marrow macrophages (BMMs) in M-CSF and 
RANKL. Total RNA was extracted on days 0, 2, 
and 4 and RT-PCR performed to detect FHL2 
mRNA. While FHL2 mRNA was nondetectable 
in BMMs, its expression was incrementally 
enhanced in WT cells as they committed to the 
osteoclast phenotype (Figure 3A). Similarly, 
FHL2 protein appears with osteoclast differen-
tiation (Figure 3B). As expected, neither FHL2 
message nor protein is demonstrable in osteo-
clasts lacking the gene. Establishing specific-
ity, FHL1, FHL4, and ACT mRNAs are unde-
tectable in BMMs and osteoclasts while FHL3 
mRNA is constitutively expressed throughout 
the process but not induced by RANKL and 
M-CSF (Figure 3C).
Endogenous FHL2 and TRAF6 interact in osteo-
clasts. Having discovered that overexpressed 
FHL2 and TRAF6 interact in transformed cells, 
we asked if the same endogenous proteins asso-
ciate in authentic osteoclasts, and if so, whether 
short-term RANKL stimulation has an impact 
on the phenomenon. Thus, BMMs or osteo-
clasts were serum- and cytokine-starved for 3 
hours and then treated with RANKL or vehicle 
for 30 minutes. Immunoblotting of TRAF6 
immunoprecipitates with anti-FHL2 antibody 
establishes that the 2 proteins associate in 
osteoclasts in a manner not impaired by acute 
RANKL exposure (Figure 4A). The intracellular 
association of TRAF6 and FHL2 is buttressed 
by their colocalization in mature osteoclasts as documented by 
immunofluorescent microscopy (Figure 4B).
FHL2 blocks RANK /TRAF6 association. The fact that FHL2 asso-
ciated with TRAF6 raised the possibility that formation of this 
complex on RANK blunts RANK/TRAF6 signaling. We tested this 
concept by first establishing that both TRAF6 (Figure 5A) and 
FHL2 (Figure 5B) associate with RANK when overexpressed in 
293T cells. TRAF6/RANK recognition is enhanced in the absence 
of FHL2 in authentic preosteoclasts, indicating that the LIM 
domain protein may blunt osteoclastogenic signals (Figure 5C).
FHL2 modulates NF-κB activity. Its association with TRAF6 in 
osteoclasts suggests FHL2 may participate in osteoclast function. 
Because the RANK/TRAF6 complex signals via NF-κB, we asked 
whether FHL2 has an impact on this transcription complex. To 
determine the impact of FHL2 on NF-κB in authentic osteoclasts, 
we turned to nuclear translocation of NF-κB, a requisite event in 
its transcriptional activity. WT or FHL2–/– BMMs were exposed 
to RANKL and M-CSF for 3 days, starved for 3 hours, and once 
again exposed to RANKL. Nuclear proteins were extracted, at 0, 
5, 15, and 30 minutes, and immunoblot was performed with an 
antibody to the p65 NF-κB subunit. As seen in Figure 6A, RANKL 
treatment induces more rapid and profound p65 nuclear translo-
cation in FHL2–/– than in WT cells.
To determine the transcriptional consequences of FHL2-restrict-
ed NF-κB activation, we assessed RANKL stimulation of selective 
NF-κB–responsive genes in WT and FHL2-deleted preosteoclasts 
(Figure 6B). In fact, RANKL-induced expression of IκBα and TNF-α 
in mRNA, both of which are the products of NF-κB target genes, 
is enhanced in the cells lacking the LIM protein. On the other 
Figure 1
TRAF proteins interact with FHL2. (A) FLAG-tagged TRAF2, TRAF4, and TRAF6 and HA-
tagged FHL2 were cotransfected into 293T cells. Protein expression level was detected by 
immunoblot with anti-FLAG and anti-HA antibodies. Cell lysates were immunoprecipitated 
with anti-FLAG antibody and the immunoprecipitates immunoblotted with anti-HA anti-
body. A specific band appears in all TRAF-containing immunoprecipitates (arrow). (B) HA-
tagged FHL2 and FLAG-tagged TRAF6 were cotransfected into 293T cells. Anti-HA anti-
body was used for immunoprecipitation and anti-FLAG antibody for immunoblotting. (C) 
The same cells described in B were subjected to immunofluorescent microscopy using an 
anti-FLAG rabbit polyclonal antibody and FITC-labeled secondary antibody (green reac-
tion product) or anti-HA monoclonal antibody and TRITC-labled secondary antibody (red 
reaction product). FHL2/TRAF6 colocalization was documented by simultaneous expo-
sure yielding the yellow reaction product (overlay). Magnification: ×200.
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hand, TNF-α, which, like RANKL, is a TNF superfamily member, 
fails to substantially distinguish p65 translocation in FHL2–/– pre-
osteoclasts relative to WT, establishing specificity of RANKL in 
the FHL2 osteoclastogenic signaling pathway (Figure 6C).
Finally, we reasoned that if its absence enhances NF-κB sig-
naling, the opposite should obtain in osteoclasts overexpress-
ing FHL2. To test this hypothesis, we retrovirally transduced 
WT BMMs with an FHL2 expression plasmid or empty vector. 
The cells were treated with M-CSF plus increasing amounts 
of RANKL for 4 days and then assayed for RANKL-dependent 
NF-κB activity. In keeping with a central role for the transcrip-
tion complex in TRAF6-stimulated osteoclast formation and 
function, overexpressed FHL2 arrests RANKL-induced IκBα 
phosphorylation (Figure 6D).
Absence of FHL2 accelerates osteoclast differentiation and cytoskeletal 
organization. These data indicate that FHL2 may delay osteoclast 
recruitment and/or function. To determine if this is so, we treat-
ed FHL2–/– and WT BMMs with increasing doses of RANKL and 
M-CSF. After 4 days, the number of characteristic, well-spread 
osteoclasts	was substantially greater in cultures derived from 
FHL2–/– mice than in those from WT mice (Figure 7, A and B). 
The enhancement of osteoclast size and spreading is particularly 
evident at lower concentrations of RANKL, indicating that FHL2 
deficiency sensitizes osteoclasts to the cytokine.The accelerated 
rate of FHL2–/– osteoclast precursor differentiation is substanti-
ated by increased expression of the 2 osteoclastogenic markers, 
NFAT2 and cathepsin K (Figure 7C).
The propensity of FHL2–/– osteoclasts to spread suggests 
enhanced organization of their cytoskeleton. To determine if 
this is so, we generated osteoclasts on dentin. Similarly to their 
appearance on plastic (Figure 7A), FHL2-deficient osteoclasts 
on the resorptive substrate are larger than WT and have more 
pronounced actin rings, a critical hallmark of cytoskeletal orga-
nization (Figure 7D).
Overexpression of FHL2 attenuates osteoclast differentiation and 
spreading. Given our findings that FHL2 deletion accelerates 
osteoclast differentiation and cytoskeletal organization, we 
predicted that overexpres-
sion of the protein would 
exert the opposite effect, 
namely, blunted matu-
ration and spreading 
of bone resorptive cells. 
As shown in Figure 8, 
control BMMs exposed 
to 50 ng/ml RANKL but 
not those overexpressing 
FHL2 differentiate into 
characteristic osteoclasts. 
At 100 ng/ml RANKL, 
the FHL2-transduced 
cells begin to undergo 
osteoclastogenesis, but 
the polykaryons failed 
to assume the spread 
configuration apparent 
in cells bearing empty 
vector.  Spreading of 
FHL2-overexpress ing 
osteoclasts is evident in 
cultures containing 200 ng/ml RANKL, but even in this circum-
stance, many cells remain unspread and the characteristic osteo-
clasts are smaller than control.
FHL2-deficient osteoclasts undergo early apoptosis. The osteoclast is a 
terminally differentiated cell and as such enjoys a defined life span. 
This being the case, one would predict that cells reaching terminal 
differentiation rapidly would also initiate early apoptosis. In fact, 
by day 4 of culture, programmed cell death is increased more than 
2-fold in osteoclasts lacking FHL2 (Figure 9A). In keeping with this 
observation, caspase 3 is activated earlier during the osteoclasto-
genic process in FHL2–/– as compared with WT cells (Figure 9B).
Figure 2
FHL2 and TRAF6 domains required for coassociation. (A) FHL2 deletion constructs were generated by muta-
genesis of full-length FHL2. FLAG-tagged TRAF6 and HA-tagged FHL2 constructs were cotransfected into 293T 
cells. Anti-HA antibody was used for immunoprecipitation and anti-FLAG antibody for immunoblotting. Deletion 
of any LIM domain of FHL2 abolishes its interaction with TRAF6. The diagram defines ∆ mutants. (B) TRAF6 
constructs were generated by PCR. FLAG-tagged full-length TRAF6 (TRAF6-full), ring domain–deleted TRAF6 
(TRAF6-NR), and the complete TRAF domain (TRAF6C) were cotransfected with HA-tagged FHL2 into 293T 
cells. Anti-HA antibody was used for immunoprecipitation and anti-FLAG antibody for immunoblotting.
Figure 3
FHL2 is induced during osteoclastogenesis. (A) WT and FHL2–/– (KO) 
BMMs were cultured in M-CSF and RANKL for up to 4 days. FHL2 
mRNA expression was determined by RT-PCR. GAPDH mRNA 
served as loading control. (B) BMMs and osteoclasts, treated as in 
A, were lysed, and FHL2 expression was determined by immunoblot. 
β-actin served as loading control. (C) BMMs were treated with M-CSF 
and RANKL for up to 4 days, and FHL family member mRNAs were 
determined by RT-PCR.
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Absence of FHL2 enhances osteoclast resorptive activity. To determine 
whether acceleration of differentiation and cytoskeletal organiza-
tion of FHL2–/– osteoclasts extends to the cells’ capacity to degrade 
bone, we generated osteoclasts from mutant and WT BMMs, on 
dentin, for 4 days. Figure 10, A and B, shows that resorptive lacu-
na formation by FHL2-deficient osteoclasts during this period is 
enhanced approximately 10-fold relative to that in WT.
These data substantiate stimulated net resorptive activity in 
the absence of FHL2 in vitro. Together with the fact that RANKL 
induces FHL2 expression by osteoclasts in vivo, they also sug-
gest that FHL2-deficient mice, treated with the cytokine, would 
resorb bone more aggressively than their WT counterparts. In 
fact, tartrate-resistant acid phosphatase 5b (TRACP 5b) serum 
levels of FHL2–/– mice treated with RANKL for 7 days are 
increased 4-fold relative to those of WT (Figure 10C). Reflect-
ing this enhanced resorptive activity, trabecular bone volume of 
RANKL-treated mutant mice is approximately one-third that of 
their WT counterparts (Figure 10D). On the other hand, there 
is no significant difference in bone mass between PBS-injected 
WT and mutant mice.
FHL2 is expressed only in activated osteoclasts in vivo. The lack of 
significant change in bone mass in PBS-injected FHL2–/– mice 
challenges the relevance of the protein in basal osteoclast func-
tion. To address this issue, we assessed FHL2 expression by 
osteoclasts in vivo. In fact, osteoclasts in naive WT mice do not 
contain detectable immunoreactive protein (data not shown). 
Because osteoclasts lacking NF-κB–inducing kinase, when 
maintained in culture, reflect the activated and not basal state 
of their in vivo counterparts (14), we asked whether the same 
obtain regarding FHL2–/– bone resorptive cells. Hence we inject-
ed soluble RANKL (100 µg/day) or PBS for 7 days into WT and 
FHL2–/– mice and once again immunostained histological sec-
tions with anti-FHL2 mAb. Similarly to naive WT mice, those 
receiving PBS contain no osteoclast-residing immunoreac-
tive FHL2 (Figure 11A). In contrast, numerous FHL2-express-
ing osteoclasts are present in the RANKL-treated animals. No 
immunostaining is detectable in megakaryocytes, the bones of 
FHL2–/– mice, or second antibody–exposed sections of RANKL-
treated animals (not shown).
The fact that FHL2 is restricted to activated osteoclasts, in 
vivo, suggests that expression of the protein by these cells may 
also be abundant in diseases of accelerated bone resorption. We 
therefore generated a murine model of inflammatory arthri-
tis, which, like that affecting humans, is characterized by peri-
articular osteolysis (15). As seen in Figure 11B, joint-residing 
osteoclasts in mice with inflammatory arthritis also contain 
an abundance of immunoreactive FHL2. Documenting that 
absence of FHL2 enhances bone resorption in the context of 
this disease, serum TRACP 5b levels are substantially greater 
in FHL2–/– than in WT arthritic mice (Figure 11C). On the 
other hand, FHL2 does not impact the numbers of osteoclasts 
in naive mice and those treated with RANKL or afflicted with 
inflammatory arthritis (data not shown). Consistent with cyto-
skeletal changes, therefore, the accelerated bone resorption in 
the mutant animals reflect stimulated osteoclast activity rather 
than enhanced recruitment.
Discussion
The discovery in 1998 that RANKL is the key osteoclastogenic 
cytokine positioned it as a principal anti–bone resorptive	target 
(2). In fact, arrest of RANK signaling has proven effective treat-
ment for postmenopausal osteoporosis (16). Thus, attention has 
turned to modulating RANKL’s consequent intracellular signals as 
a reasonable therapeutic strategy.
Figure 4 
FHL2 interacts with TRAF6 in osteoclasts. (A) WT BMMs and 
day 4 osteoclasts were starved for 3 hours and maintained 
with and without RANKL (100 ng/ml) for 30 minutes. TRAF6 
was immunoprecipitated from lysates and the immunoprecipi-
tate blotted with anti-FHL2 or anti-TRAF6 antibodies. Lysate 
content of the 2 proteins was determined by immunoblot. (B) 
Mature osteoclasts (day 5) were subjected to immunofluores-
cent microscopy using an anti-TRAF6 rabbit polyclonal anti-
body and FITC-labeled secondary antibody (green reaction 
product) or anti-FHL2 monoclonal antibody and TRITC-labled 
secondary antibody (red reaction product). FHL2/TRAF6 colo-
calization was documented by simultaneous exposure yielding 
the yellow reaction product (overlay). Magnification: ×200.
Figure 5
FHL2 inhibits TRAF6/RANK association in osteoclasts. FLAG-tagged 
TRAF6, FLAG-tagged FHL2, and HA-tagged RANK were cotransfect-
ed, in various combinations, into 293T cells. Protein expression was 
determined by anti-FLAG or anti-HA antibodies. Anti-FLAG antibody 
was used for immunoprecipitation and anti-HA for immunoblotting. (A) 
TRAF6 interacts with RANK. (B) FHL2 interacts with RANK. (C) After 
4 days of exposure to M-CSF and RANKL, WT and FHL2–/– cells were 
lysed. Equal amounts of lysate were immunoprecipitated with anti-
TRAF6 antibody and the immunoprecipitate blotted with anti-RANK or 
anti-TRAF6 antibodies. Total cell lysate content of RANK, TRAF6, and 
FHL2 were determined by immunoblot.
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RANKL’s receptor, RANK, is a component of the TNF recep-
tor superfamily and, like all other members, has a cytoplasmic 
domain that associates with TRAFs (17). These adaptor molecules 
regulate cytokine signaling by linking TNF family receptors with 
downstream protein kinases, ubiquitin ligases, and other effector 
proteins (17). A total of 6 mammalian TRAFs are in hand, and all 
but TRAF4 recognize RANK. RANK binds TRAFs 1, 2, 3, and 5 at 
a multiple TRAF-binding site in its carboxyl terminal region (18). 
In contrast, TRAF6 targets a separate region of RANK, a domain 
essential for RANKL’s effect on the osteoclast (19).
We initiated this study with the aim of identifying cellular pro-
teins that associate with TRAF4. Our rationale for this under-
taking was the fact that, while TRAF4 is not known to bind any 
recognized receptor, mice deficient in the protein have skeletal 
malformations (20). Thus, our aim was to begin to delineate the 
means by which TRAF4 regulates the skeleton by detailing mol-
ecules to which it complexes. To this end, we turned to a yeast 
2-hybrid assay and discovered that TRAF4 associates with the 
LIM domain–only protein, FHL2.
LIM domain proteins typically serve as adaptors and scaffolds 
for multimolecular complexes (21, 22). They contain various com-
binations of 2 tandemly repeated zinc fingers with which they 
recognize their binding partners. FHL2 belongs to a subgroup of 
5 homologous LIM domain–only proteins consisting exclusively 
of FHLs (23). It has been linked with tumorigenesis, cell differen-
tiation, and nuclear receptor regulation (24). The protein, while 
originally believed expressed exclusively in heart (23), is also found 
in striated muscle (25) and, relevant to the present paper, in a 
myeloid cell line (26). FHL2 is localized within both the cytoplasm 
and the nucleus and shuttles between these compartments (24). 
In the nucleus, FHL2 serves as a cell and promoter-specific tran-
scriptional coactivator or corepressor through its interaction with 
transcription factors such as the androgen receptor (27), activator 
protein-1 (28), cAMP response element binding protein (CREB) 
and CREM (29), and β-catenin (30, 31).
Each TRAF contains a TRAF domain, the carboxyl terminal 
of which mediates protein/protein interactions (5). Because the 
TRAF domains of TRAF4 and TRAF6 diverge from those of the 
other 4 family members, we reasoned they would recognize dis-
tinct partners. Indeed, TRAF6, via its TRAF domain, binds FHL2 
and does so with apparently greater efficiency relative to expressed 
protein than either TRAF2 or TRAF4. This selectivity of FHL2 
by TRAF6 and the central role this latter adaptor protein plays 
in osteoclast biology prompted us to focus on the interaction 
between the 2 molecules and how they, in combination, regulate 
the osteoclast. In fact, FHL2, specific among its subfamily of LIM 
domain–only proteins, increases pari passu with osteoclast dif-
ferentiation. FHL2 also binds and colocalizes with TRAF6 in the 
differentiated cell and dose dependently inhibits its association 
with RANK. Given the importance of TRAF6 in RANK signal-
ing, these observations suggested that FHL2 may have an impact 
on the osteoclast. To determine whether this is so, we turned to 
FHL2–/– mice and discovered that absence of the protein accel-
erate osteoclast differentiation. We also found that apoptotic 
changes appear in FHL2–/– osteoclasts earlier than in their WT 
counterparts. Two possible explanations for the accelerated death 
of these mutant cells present themselves. In the first instance, 
RANKL induces apoptosis of osteoclast-like cells through TRAF6 
(32), whose association with RANK is blunted by FHL2. Second, 
osteoclasts are terminally differentiated and incapable of mitotic 
activity. Because the absence of FHL2 prompts the cell to rapidly 
reach its ultimate state of differentiation, the polykaryon will also 
die earlier. This combination of accelerated differentiation and 
early death suggests that the longevity of FHL2–/– osteoclasts mir-
rors that of WT cells, which is also consonant with the similarity 
of osteoclast numbers in both genotypes in vivo.
NF-κB activation is an essential component of the osteoclasto-
genic process (33). Consistent with accelerated osteoclast precur-
sor differentiation, nuclear translocation of the p65 subunit of the 
transcription complex is enhanced in FHL2-deficient osteoclast 
precursors. Moreover, FHL2 overexpression in osteoclasts blunts 
RANKL-stimulated IκBα phosphorylation. Thus, arrest of TRAF6-
mediated NF-κB activation is likely to be an essential component 
of the antiosteoclastogenic properties of FHL2.
Figure 6 
FHL2 modulates NF-κB activity. WT and FHL2–/– BMMs were cultured with M-CSF and RANKL. On day 3, the cells were starved for 3 
hours and then stimulated with RANKL (100 ng/ml) for up to 2 hours. (A) Nuclear proteins were extracted and NF-κB subunit p65 content 
was determined by immunoblot. α-Nucleophosmin served as loading control. (B) IκBα and TNF-α mRNA expression was determined by 
RT-PCR. GAPDH mRNA served as loading control. (C) WT and FHL2–/– BMMs were cultured with M-CSF and RANKL. On day 3, the cells 
were starved for 3 hours and then stimulated with TNF-α (10 ng/ml) at 0, 5, 15, and 30 minutes. Nuclear proteins were extracted, and NF-κB 
subunit p65 content was determined by immunoblot. α-Nucleophosmin served as loading control. (D) WT BMMs were retrovirally transduced 
with empty vector (PMX) or vector expressing FHL2 and selected with blasticidin S, hydrochloride for 3 days. Selected cells were starved for 
3 hours and stimulated with RANKL (100 ng/ml) for up to 30 minutes. Phosphorylated (p) and total (T) IκBα were determined by immunoblot. 
β-actin served as loading control.
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Despite the central role enjoyed by TRAF6 in regulating the 
osteoclast, its precise impact on the resorptive cell is controver-
sial because of the varied phenotypes of mice lacking the adaptor 
protein. As expected, TRAF6–/– mice are osteopetrotic regardless of 
strain and one group posits that their failure to resorb bone rep-
resents an absence of osteoclasts (9). Alternatively, another labora-
tory claims that TRAF6-deficient osteoclasts are generated but are 
dysfunctional, as they do not attach to bone, a likely cytoskeletal 
defect (8). While this discrepancy remains to be resolved, it may 
relate to the fact that RANKL has an impact not only on commit-
ment of macrophages to the osteoclast phenotype but also on acti-
vation of mature osteoclasts. In this regard, Armstrong et al. report 
that TRAF6 is essential for osteoclast cytoskeletal organization 
and resorptive function but that partial redundancy exists among 
the various TRAFs in RANKL-mediated osteoclast differentiation 
(34). In fact, FHL2 has an impact on the osteoclast cytoskeleton as 
evidenced by either its deletion or excess. Specifically, osteoclasts 
lacking FHL2 have accelerated formation of large actin rings. This 
cytoskeletal structure isolates the resorptive microenvironment 
from the general extracellular space and is essential for optimal 
bone degradation, as it is absent in disorders of osteoclast function 
such as that characterizing deletion of the β3 integrin (35). In this 
regard, FHL2 expression by osteoclasts is similar to that of the β3 
integrin by endothelial cells	(36–38). Both proteins are abundant 
in culture but absent in naive cells in vivo, only to appear in states 
of cellular activation. These observations underscore the likeli-
hood that discrepancies between gene expression in vitro and in 
naive animals represent a global activating effect of culture. Such a 
circumstance is also evident as regards the osteoclastogenic capac-
ity of NF-κB–inducing kinase–deficient mice (14).
Similar to other molecules, such as SHIP-1 (39), which physi-
ologically restrain osteoclast function, deletion of FHL2 results in 
exaggerated cytoskeletal organization leading to hyperresorptive 
osteoclasts and, in vivo, a deficit of bone mass following RANKL 
treatment. In contrast, yet also in keeping with inhibition of 
TRAF6-mediated differentiation and cytoskeletal organization, 
FHL2 overexpression desensitizes osteoclast precursors to RANKL, 
consequently limiting their differentiation and the ability of the 
polykaryons to spread effectively.
These studies expand our knowledge of the RANK signaling 
pathway and underscore the importance of TRAF6-associated pro-
teins in regulating the osteoclast. Finally, FHL2 joins a growing 
collection of molecules not suspected of participating in skeletal 
biology that ultimately prove to be modulators of bone cell func-
tion and thus potential therapeutic targets, particularly in states 
of accelerated resorption.
Figure 7
Absence of FHL2 accelerates osteoclast differentiation and cytoskeletal organization. (A) BMMs derived from WT and FHL2–/– mice were maintained 
for 4 days in M-CSF and increasing concentrations of RANKL. The cells were then stained for TRAP activity to determine the relative numbers of char-
acteristic spread osteoclasts (arrows). (B) Quantitative data derived from experiment detailed in A comparing the numbers of characteristic spread 
osteoclasts (OCs) as a function of RANKL concentration. Inset shows characteristic spread and nonspread osteoclasts, respectively. *P < 0.05; 
**P < 0.01. (C) BMMs derived from WT and FHL2–/– mice were maintained for up to 4 days in M-CSF plus RANKL. Equal amounts of lysate were 
immunoblotted for NFAT2 and cathepsin K (CathK) content. β-actin serves as loading control. (D) WT and FHL2–/– BMMs were cultured on dentin 
with M-CSF and RANKL. On day 4, the cells were fixed and actin ring formation was assessed by rhodamine-phalloidin staining. Magnification: 
×200 (A) and ×600 (B and D).
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Methods
Mice. FHL2–/– and WT mice	on the hybrid Black Swiss-129-SV/J background 
were the products of heterozygous crosses (40). Animals were housed in the 
animal care unit of the Department of Pathology, Washington University 
School of Medicine, and were maintained according to guidelines of the 
Association for Assessment and Accreditation of Laboratory Animal Care.
All animal experimentation was approved by the Animal Studies Commit-
tee of Washington University School of Medicine.
Reagents. Recombinant murine M-CSF was from R&D Systems. Murine 
glutathione-S-transferase–RANKL was expressed in our laboratory as 
described previously (4). Anti-HA antibody was obtained from Covance 
Research Products. Anti-TRAF6 and anti-NFAT2 antibodies were obtained 
from Santa Cruz Biotechnology Inc. Antiactivated and anti–total caspase 3	
antibodies were obtained from Cell Signaling Technology. All other chemi-
cals were obtained from Sigma-Aldrich.
Two-hybrid library screening. A full-length TRAF4 coding sequence was 
cloned into pGBT9 (BD Biosciences — Clontech) to generate the pGBT9/
TRAF4 bait plasmid. The mouse embryo pACT2 cDNA library (a generous 
gift from Xu Cao, University of Alabama at Birmingham, Birmingham, 
Alabama, USA) was screened according to the manufacturer’s instructions 
(BD Biosciences — Clontech).
Plasmids. TRAF2, TRAF4, and TRAF6 cDNA were obtained by RT-PCR and 
PCR from a murine primary osteoblast cDNA library generated in our labo-
ratory. All TRAFs were coupled to FLAG tag (Sigma-Aldrich) at the C termi-
nal in PcDNA3 vector (Invitrogen Corp.). RANK-HA plasmid was generated 
in our laboratory. FHL2 cDNA was recovered from the yeast 2-hybrid assay 
and was linked with either FLAG or HA at C terminal in PcDNA3 vector.
Immunoprecipitation and Western blot. FLAG-tagged full-length and 
truncated TRAF6, FLAG tagged FHL2, and HA-tagged full-length and 
truncated FHL2 cDNAs were subcloned into the mammalian expres-
sion vector pcDNA3 (Invitrogen Corp.). 293T cells were transfected 
with expression constructs using Fugene 6 as the transfection reagent 
according to the manufacturer’s instructions (Promega). Cells were lysed 
48 hours after transfection, and lysates were immunoprecipitated and 
immunoblotted with anti-FLAG or anti-HA antiserum. Anti-TRAF6, 
anti-FHL2, and anti-RANK antibodies were used to detect endogenous 
protein-protein interaction. Nuclear p65 translocation experiments were 
performed by using lysates of preosteoclasts generated by exposure of 
BMMs to M-CSF and RANKL for 3 days.
Immunofluorescence. Intracellular TRAF6 and FHL2 were labeled with 
fluorescent markers as described (41). In brief, cells were fixed with 3% 
paraformaldehyde in PBS for 20 minutes. Free aldehyde groups were 
quenched with 50 mM NH4Cl in PBS for 10 minutes. Nonspecific bind-
ing was blocked by incubation in PBS containing 0.2% bovine serum 
albumin and 0.05% saponin (PBSBS) for 15 minutes. The cells were then 
incubated with primary antibodies in PBSBS for 1 hour. Primary anti-
body binding was visualized using fluorescent dye–conjugated secondary 
antibodies (Jackson ImmunoResearch Laboratories Inc.) in PBSBS for 
45 minutes. Immunofluorescence analysis was performed using a Nikon 
fluorescence microscope equipped with a CCD camera. Primary antibod-
ies used include rabbit anti-FLAG (Sigma-Aldrich), monoclonal anti-HA 
(Covance Research Products), monoclonal anti-FHL2, and polyclonal 
anti-TRAF6 (Santa Cruz Biotechnology Inc.).
Primary cells and cell lines. Macrophages/osteoclast precursors and osteo-
clasts were generated from bone marrow precursors as described (42). C2C12 
and 293T cells were obtained from ATCC and were maintained as described.
Characterization of osteoclasts. BMMs were cultured in 96-well cell culture 
dishes in the presence of M-CSF (10 ng/ml) and RANKL (100 ng/ml or 
Figure 8
FHL2 overexpression attenuates osteoclast differen-
tiation and spreading. BMMs were retrovirally trans-
duced with empty vector or vector expressing FHL2 
and selected with blasticidin S, hydrochloride for 3 
days. Selected cells were stimulated with M-CSF and 
increasing doses of RANKL for 4 days after which the 
cultures were stained for TRAP activity. Arrows point 
to nonspread osteoclasts. Magnification: ×400.
Figure 9
FHL2-deficient osteoclasts undergo early apoptosis. WT and FHL2–/– BMMs were cultured in M-CSF and RANKL. (A) The magnitude of 
apoptosis was measured by ELISA 4 days later. **P < 0.01. (B) Activated and total caspase 3 were measured by immunoblot with time. 
β-actin served as loading control.
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doses detailed in figure legends). Media were changed on day 3. Osteo-
clast-like cells were characterized by staining for tartrate-resistant acid 
phosphatase (TRAP) activity. The number of osteoclasts was counted as 
described previously (42). The characteristics of spread as compared to 
nonspread osteoclasts are illustrated in Figure 7B.
RNA extraction and amplification by RT-PCR. BMMs were exposed to 
M-CSF and RANKL for various times as detailed in figure legends. 
RNA purification and RT-PCR conditions were as described previ-
ously (42). The oligonucleotide primers used are as follows: FHL1, 
5 ′-GTTTCACCGCTGTGGAGGAC, 3 ′-GAGGGAGGGAGGGAG-
CAAAG; FHL2, 5′-CCCCATTAGTGGTCTGGGTG, 3′-CCAGGGCAG-
CAAGAGGAAGC;  FHL3,  5 ′ -GCGCCCCATCGTAGGACTCG, 
3 ′ - C G T T C T A G G G A G G G G T T G G G ;  F H L 4 ,  5 ′ - G G G T G -
CAAGAACCCCATCAC, 3′-GGAGCAGCTTCACAGAGGTG; ACT, 5′-
GCCTGCTGTGCACAGACTGC, 3′-GGGTTTGGTGCAGGCTGCAC.
Bone resorption. Osteoclasts were generated on whale dentin slices from 
BMMs under conditions described above. After 4 days the cells were 
stained for TRAP activity. For actin-ring staining, cells were fixed in 4% 
paraformaldehyde, permeabilized in 0.1% Triton X-100, rinsed in PBS, and 
immunostained with Alexa 488 phalloidin (Invitrogen Corp.). To quan-
titate resorption lacunae, cells were removed from the dentin slices with 
0.5 M ammonium hydroxide and mechanical agitation. Dentin slides were 
stained with Coomassie brilliant blue.
Figure 10
Absence of FHL2 enhances osteoclast resorptive 
activity and RANKL-stimulated bone loss. (A) WT 
and FHL2–/– BMMs were cultured on dentin with 
M-CSF and RANKL. Resorption lacuna formation 
was examined on day 4 by Coomassie brilliant 
blue staining. Magnification: ×200. (B) Quantita-
tive analysis of experiment detailed in A. Pit area 
(%), percentage of dentin surface occupied by 
resorption lacunae. (C) WT and FHL2–/– mice were 
administered 100 µg RANKL subcutaneously for 7 
days. Serum TRACP 5b levels were determined by 
ELISA. (D) WT and FHL2–/– mice were administered 
PBS (control) or RANKL (100 µg) daily for 7 days. 
The tibiae were recovered on day 9 and trabecu-
lar bone volume (BV/TV) determined by micro-CT. 
*P < 0.05; **P < 0.01.
Figure 11
FHL2 is expressed only in activated osteoclasts. (A) WT mice were 
administered PBS or RANKL (100 µg/day) for 7 days. On day 9, histo-
logical sections of tibiae were stained for TRAP activity (red reaction 
product) or immunostained using an anti-FHL2 mAb. Osteoclasts in 
the RANKL-treated, but not PBS-treated, mice stained positive for the 
brown reaction product. (B) Serum transfer inflammatory arthritis was 
induced in WT mice. After 7 days, histological sections of the inflamed 
joints were immunostained for FHL-2, which is present in osteoclasts. 
(C) WT and FHL2–/– mice were administered arthrogenic serum to 
induce inflammatory arthritis or PBS as control. Serum TRACP 5b 
levels were measured at days 0, 7, and 14. *P < 0.05 vs. WT serum. 
Magnification: ×400.
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Cell stimulation and immunoblotting. For NF-κB signaling experiments, pri-
mary macrophages were infected with empty vector or FHL2-expressing 
retrovirus (43). Infected cells were selected by blasticidin S, hydrochloride 
(BSR) for 3 days and starved for 3 hours. RANKL (100 ng/ml) was added 
to the media, cells were lysed at 0, 5, 15, and 30 minutes,	and the lysate was 
subjected to immunoblotting.
RANKL-stimulated bone loss in vivo. RANKL (100 µg per mouse per day) 
or PBS, as control, was injected subcutaneously once per day for 7 days. 
Two days after the final injection, mice were sacrificed by CO2 narcosis 
and the tibias, devoid of soft tissue, were used to determine trabecular 
bone volume by micro-CT.
Cell death detection assay. Cell death detection assay was performed accord-
ing to the protocol of the Cell Death Detection ELISA kit (Roche Diagnostics 
Corp.). In brief, WT and FHL2–/– (KO) BMMs were cultured in 48-well plates 
(1.5 × 104 cells/well) in M-CSF and RANKL (100 ng/ml) for 4 days. On days 4 
and 5, cells were lysated and centrifuged, respectively, at 200 g for 10 minutes. 
Supernants (20 µl) were mixed with 80 µl immunoreagent for 2 hours with 
shaking at room temperature. The solution was aspirated, and the wells were 
washed 3 times with 300 ml incubation buffer. Substrate solution (100 µl) 
was added to each well and incubated on a plate shaker at 250 rpm until 
color development was complete. The absorbance was read at 405 nm.
Immunohistochemical staining. The PBS- and RANKL-injected FHL2 WT 
and FHL2–/– mice trabecular bone tissues were paraffin embedded and 
cut into 5-µm sections. Samples were briefly treated with hydrogen per-
oxide to block endogenous peroxidase. Antigen retrieval method was 
used. To lessen nonspecific binding, the samples were blocked with a 
mouse Ig reagent. Monoclonal FHL2 antibody was diluted 1:100 and 
incubated at 4°C overnight, followed by incubation with biotinylated 
anti-mouse second antibody using a Vectastain Elite ABC kit (Vector 
Laboratories) according to the manufacturer's protocol. The samples 
were developed with diaminobenzidine peroxidase substrate and coun-
terstained with hematoxylin. The samples were mounted and cover-
slipped. As another negative control, the FHL2 WT samples injected 
with either PBS or RANKL were without primary antibody but using 
secondary biotinylated.
Inflammatory arthritis model and serum TRACP 5b assay. Serum transfer 
inflammatory arthritis was induced as described (44). To determine 
bone resorptive activity in vivo, RANKL (100 µg/mouse/day) or PBS was 
injected subcutaneously once per day for 7 days. Two days after the final 
injection, serum was collected. TRACP 5b concentration was determined 
according to the protocol of the Mouse TRAP Assay kit (Immunodiag-
nostic Systems Ltd.).
Statistics. Data are expressed as mean ± SD. Statistical significance was 
determined by 2-tailed Student’s t test. P < 0.05 was considered statisti-
cally significant.
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